Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 2-3/2005

01-06-2005

Relationship of Five Inflammatory Gene Polymorphisms with Morbidity and Mortality in 533 Patients Admitted to an ICU

Authors: Jan R. Ortlepp, Jürgen Graf, Katharina Vesper, Fabian Schmitz, Vera Mevissen, Sebastian Sucigan, Alexander Kersten, Christian Weber, Uwe Janssens

Published in: Inflammation | Issue 2-3/2005

Login to get access

Abstract

Background

The aim of this study was to analyze the association of polymorphisms of five candidate genes with the outcome of consecutive patients admitted to a medical ICU.

Materials and Methods

The study population was prospectively recruited. Inclusion criteria were admission to the ICU and written informed consent by the patients or their relatives. A total of 533 patients were recruited. The morbidity was assessed by SAPS II Score. Outcome data of in hospital mortality and length of ICU and hospital stay were obtained. Genotyping for genetic polymorphisms (CRP 1059, IL1B −511, CTGF −477, CCR2 64VI, IL6 −174) were performed by allele-specific fluorogenic oligonucleotide probes (TaqMan analysis).

Results

All of the investigated polymorphisms were not associated with an altered outcome. There was no difference in morbidity and ICU or in-hospital mortality (neither in cross tabs analysis nor in Kaplan Meier or Cox regression analysis including age, gender and diagnosis as covariates) between the different genotypes.

Conclusions

Genotyping of the investigated polymorphism for risk stratification of patients admitted to ICU does not seem to be appropriated.
Literature
1.
Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809.PubMedCrossRef
2.
3.
Ridker, P. M. 2001. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 358:946–948.PubMedCrossRef
4.
Mehta, J. L., T. G. P, Saldeen, and K. Rand. 1998. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J. Am. Coll. Cardiol. 31:1217–1225.PubMedCrossRef
5.
Rupprecht, H. J., S. Blankenberg, C. Bickel, G. Rippin, G. Hafner, W. Prellwitz, W. Schlumberger, and J. Meyer. 2001. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 104:25–31.PubMed
6.
Mira, J. P., A. Cariou, F. Grall, C. Delclaux, M. R. Losser, F. Heshmati, C. Cheval, M. Monchi, J. L. Teboul, F. Riche, G. Leleu, L. Arbibe, A. Mignon, M. Delpech, and J. F. Dhainaut. 1999. Association of TNF2, a TNF-alpha promotor polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282:561–568.PubMedCrossRef
7.
Tang, G. J., S. L. Huang, H. W. Yien, W. S. Chen, C. W. Chi, C. W. Wu, W. Y. Lui, J. H. Chiu, and T. Y. Lee. 2000. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit. Care. Med. 28:2733–2736.PubMedCrossRef
8.
Yende, S., M. W. Quasney, E. Tolley, Q. Zhang, and R. G. Wunderink. 2003. Association of tumor necrosis factor gene polymorphism and prolonged mechanical ventilation after coronary artery bypass surgery. Crit. Care. Med. 31:133–140.PubMedCrossRef
9.
Ohnishi, H., T. Oka, S. Kusachi, T. Nakanishi, K. Takeda, M. Nakahama, M. Doi, T. Murakami, Y. Ninomiya, M. Takigawa, and T. Tsuji. 1998. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J. Mol. Cell Cardiol. 30:2411–2422.PubMedCrossRef
10.
Blom, I. E., A. J. van Dijk, R. A. de Weger, M. G. J. Tilanus, and R.Goldschmeding. 2001. Identification of human ccn2* (connective tissue growth factor) promoter polymorphism. J. Clin. Pathol.: Mol. Pathol. 54:192–196.CrossRef
11.
Abdi, R., T. T. B. Huong, A. Shagun-Ruiz, P. M. Murphy, B. M. Brenner, E. L. Milford, and D. H. McDermott. 2002. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J. Am. Soc. Nephrol. 13:754–758.PubMed
12.
Ortlepp, J. R., K. Vesper, V. Mevissen, F. Schmitz, U. Janssens, A. Franke, P. Hanrath, C. Weber, K. Zerres, and R. Hoffmann. 2003. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J. Mol. Med. 81:363–367.PubMedCrossRef
13.
Ridker, P. M., R. J. Glynn, and C. H. Hennekens. 1998. C-reactive Protein adds to predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97:2007–2011.PubMed
14.
Cao, H., and R. A. Hegele. 2000. Human C-reactive protein (CRP) 1059 G/C polymorphism. J. Hum. Genet. 45:100–101.PubMedCrossRef
15.
Zee, R. Y. L., and P. M. Ridker. 2002. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 162:217–219.PubMedCrossRef
16.
Read, R. C., N. J. Camp, F. S. diGiovine, R. Borrow, E. B. Kaczmarski, A. G. A. Chaudhary, J. F. Andrew, and G. W. Duff. 2000. An Interleukin-1 genotype is associated with fatal outcome of menigococcal disease. J. Infect. Dis. 182:1557–1560.PubMedCrossRef
17.
Ma, P., D. Chen, J. Pan, and B. Du. 2002. Genomic polymorphism within interleukin-1 family cytokines influence the outcome of septic patients. Crit. Care Med. 30:1046–1050.PubMedCrossRef
18.
Brull, D. J., H. E. Montgomery, J. Sanders, S. Dhamrait, L. Luong, A. Rumley, G. D. Lowe, and S. E. Humphries. 2001. Interleukin-6 gene 174G>C and 572G>C promoter polymorphism are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 21:1458–1463.PubMed
19.
Ortlepp, J. R., J. Metrikat, K. Vesper, V. Mevissen, F. Schmitz, M. Albrecht, P. Maya-Pelzer, P. Hanrath, K. Zerres, and R. Hoffmann. 2003. The interleukin 6 promotor polymorphism is associated with elevated leukocytes and reduced physical fitness in young healthy smokers. J. Mol. Med. 81:578–584.PubMedCrossRef
20.
Le Gall, J. R., S. Lemeshow, and F. Saulnier. 1993. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963.PubMedCrossRef
21.
Schlüter, B., C. Raufhake, M. Erren, H. Schotte, F. Kipp, S. Rust, H. VanAken, G. Assmann, and E. Berendes. 2002. Effect of the interleukin-6 promotor polymorphism (174 G/C) on the incidence and outcome of sepsis. Crit. Care. Med. 30:32–37.PubMedCrossRef
22.
Burzetta, F., L. Iacoviello, A. DiCastenuovo, F. Glieca, N. Luciani, R. Zamparelli, R. Schiavello, M. B. Donati, A. Maseri, G. F. Possati, and F. Andreotti. 2001. Relation of the 174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am. J. Cardiol. 88:1125–1128.CrossRef
23.
D'Aiuto, F., J. P. Casas, T. Shab, S. E. Humphries, A. D. Hingorani, and M. S. Tonetti. 2005. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 179:413–417.PubMedCrossRef
24.
Eklund, C., F. Jahan, T. Pessi, T. Lehtimaki, and M. Hurme. 2003. Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur. Cytokine Netw. 14:168–171.PubMed
25.
Lee, S. H., C. G. Ihm, S. D. Sohn, T. W. Lee, M. J. Kim, G. Koh, S. J. Oh, J. T. Woo, S. W. Kim, J. W. Kim, Y. S. Kim, B. C. Lee, S. D. Kim, B. S. Cho, H. J. Lee, and J. H. Chung. 2004. Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. Am. J. Nephrol. 24:410–414.PubMedCrossRef
26.
Halverstadt, A., D. A. Phares, S. Roth, R. E. Ferrell, A. P. Goldberg, and J. M. Hagberg. 2005. Interleukin-6 genotype is associated with high-density lipoprotein cholesterol responses to exercise training. Biochim. Biophys. Acta 1734:143–151.PubMed
27.
Vozarova, B., J. M. Fernandez-Real, W. C. Knowler, L. Gallart, R. L. Hanson, J. D. Gruber, W. Ricart, J. Vendrell, C. Richart, P. A. Tataranni, and J. K. Wolford. 2003. The interleukin-6 (−174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum. Genet. 112:409–413.PubMed
28.
Rundek, T., M. S. Elkind, J. Pittman, B. Boden-Albala, S. Martin, S. E. Humphries, S. H. Juo, and R. L. Sacco. 2002. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 33:1420–1423.PubMedCrossRef
29.
Aegerter, P., A. Boumendil, A. Retbi, E. Minvielle, B. Dervaux, and B. Guidet. 2005. SAPS II revisited. Intensive Care Med. 31:416–423.PubMedCrossRef
30.
Metadata
Title
Relationship of Five Inflammatory Gene Polymorphisms with Morbidity and Mortality in 533 Patients Admitted to an ICU
Authors
Jan R. Ortlepp
Jürgen Graf
Katharina Vesper
Fabian Schmitz
Vera Mevissen
Sebastian Sucigan
Alexander Kersten
Christian Weber
Uwe Janssens
Publication date
01-06-2005
Published in
Inflammation / Issue 2-3/2005
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-006-9000-4

Other articles of this Issue 2-3/2005

Inflammation 2-3/2005 Go to the issue

OriginalPaper

Analysis of Signal Transduction Pathways in Macrophages Using Expression Vectors with CMV Promoters: A Cautionary Tale

OriginalPaper

Circulating Levels of Urokinase-Type Plasminogen Activator (uPA) and its Soluble Receptor (suPAR) in Patients with Atopic Eczema/Dermatitis Syndrome

OriginalPaper

The Role of Endogenous Histamine on the Pathogenesis of the Lipopolysaccharide (LPS)-Induced, Acute Lung Injury: A Pilot Study

OriginalPaper

Oral Temperature in Daily Life. A New Look in the Era of Microinflammation

OriginalPaper

Effect of Fish or Soybean Oil-Rich Diets on Bradykinin, Kallikrein, Nitric Oxide, Leptin, Corticosterone and Macrophages in Carrageenan Stimulated Rats

OriginalPaper

Interferon γ-Induced Gene Expression of the Novel Secretory Phospholipase A2 Type IID in Human Monocyte-Derived Macrophages is Inhibited by Lipopolysaccharide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits